Login to Your Account



Teva Loses Copaxone Patent Case, Boosting Momenta Stock

By Catherine Shaffer
Staff Writer

Tuesday, July 30, 2013
In a patent infringement appeal filed by Momenta Pharmaceuticals Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals, the Court of Appeals for the Federal Circuit declared some patents for Teva Pharmaceutical Industries Ltd.'s multiple sclerosis (MS) drug, Copaxone (glatiramer acetate injection), to be invalid.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription